Religare Enterprises Q1 Results: Consolidated loss widens to ₹7,673 lakh

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights

Religare Enterprises reported a consolidated net loss of ₹7,672.94 lakh for Q1FY26, reversing a profit of ₹573.25 lakh in Q1FY25. Standalone losses also widened to ₹961.97 lakh. Consolidated revenue rose to ₹2,35,339.81 lakh. Total comprehensive income remained positive at ₹2,712.04 lakh despite the net loss.

powered bylight_fuzz_icon
48150630

*this image is generated using AI for illustrative purposes only.

Religare Enterprises Limited reported a consolidated net loss of ₹7,672.94 lakh for the quarter ended June 30, 2026, marking a significant shift from the net profit of ₹573.25 lakh recorded in the corresponding quarter of the previous fiscal year. The company’s standalone operations also incurred a loss, with the standalone net loss widening to ₹961.97 lakh from ₹614.83 lakh in Q1FY25.

The Board of Directors approved the unaudited standalone and consolidated financial results during a meeting held on August 12, 2026. The results were subsequently published on the stock exchanges on August 13, 2026, in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Overview

Consolidated revenue from operations stood at ₹2,35,339.81 lakh for the quarter, up from ₹1,87,152.12 lakh in Q1FY25. Despite the growth in top-line figures, the bottom line deteriorated sharply, swinging from a profit to a substantial loss year-on-year.

On a standalone basis, total revenue from operations was ₹251.68 lakh, a significant increase from ₹24.01 lakh reported in the same period last year. However, this revenue did not translate into profitability, as the company continued to face operational headwinds.

Metric Consolidated Q1FY26 (₹ Lakh) Consolidated Q1FY25 (₹ Lakh) Standalone Q1FY26 (₹ Lakh) Standalone Q1FY25 (₹ Lakh)
Total Revenue from Operations 2,35,339.81 1,87,152.12 251.68 24.01
Net Profit / (Loss) Before Tax (7,672.94) 573.25 (961.97) (614.83)
Total Comprehensive Income 2,712.04 3,825.50 (961.88) (621.67)

What the Numbers Show

A notable divergence exists between the company’s comprehensive income and its net profit figures on a consolidated basis. While the consolidated net loss widened significantly to ₹7,672.94 lakh, the total comprehensive income remained positive at ₹2,712.04 lakh. This suggests that other comprehensive income items, such as revaluation gains or foreign currency translation adjustments, offset the operational losses for the period. In contrast, the standalone entity showed no such offset, with both net loss and comprehensive income remaining negative.

Share Capital and EPS

The paid-up equity share capital increased slightly to ₹34,123.37 lakh as of June 30, 2026, from ₹33,289.05 lakh at the end of FY26. Earnings per share (EPS) turned negative for the quarter. Basic and diluted EPS on a consolidated basis were (₹0.78), down from (₹0.31) in Q1FY25. On a standalone basis, basic and diluted EPS were (₹0.29), compared to (₹0.19) in the prior year quarter.

Historical Stock Returns for Religare Enterprises

1 Day5 Days1 Month6 Months1 Year5 Years
-0.69%+8.58%-2.01%+17.08%+2.72%+61.66%

What specific operational cost drivers or margin pressures caused the bottom line to deteriorate despite a 25% year-on-year increase in consolidated revenue?

How will the significant divergence between the consolidated net loss and positive comprehensive income impact Religare's balance sheet strength and future valuation metrics?

Given the widening standalone losses, what strategic restructuring or divestment plans is management considering to improve core operational profitability?

Religare Enterprises grants 13,195 ESOPs at ₹227.35 per share

scanx
Reviewed by
Riya DScanX News Team
Key Highlights

Religare Enterprises Limited granted 13,195 stock options to employees under its 2019 ESOP scheme on August 12, 2026. The options vest in five equal annual installments with an exercise price of ₹227.35 per share. The grant complies with SEBI Listing Regulations and does not currently impact diluted EPS as no options have been exercised.

powered bylight_fuzz_icon
48067409

*this image is generated using AI for illustrative purposes only.

The Nomination and Remuneration Committee of Religare Enterprises approved the grant of 13,195 stock options to eligible employees under the company’s Employee Stock Option Plan 2019 during a meeting held on August 12, 2026. This equity incentive move aligns employee interests with shareholder value creation, as the options carry an exercise price of ₹227.35 per share and vest over a five-year period.

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The scheme itself conforms to the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, having received prior approval from both the Board of Directors and shareholders. Each stock option is convertible into one equity share with a face value of ₹10.

Key Terms of the Grant

The structural details of the option grant are outlined below:

Parameter Details
Total Options Granted 13,195
Exercise Price ₹227.35 per share
Vesting Schedule 5 equal annual installments (20% each)
First Vesting Date Completion of one year from grant date
Maximum Tenor 8 years from date of vesting

Under the vesting schedule, 2,639 options will vest annually for five consecutive years, starting one year after the grant date. Employees must exercise their vested options no later than eight years from the respective vesting dates. As of the filing date, no options have been exercised, lapsed, or cancelled, and there have been no variations to the terms of the options.

Impact on Shareholder Metrics

Since the options remain unexercised, they do not currently impact the diluted earnings per share (EPS) or the total number of outstanding shares. The potential dilution will only materialize if and when employees exercise their rights to convert the options into equity shares. The fixed exercise price of ₹227.35 serves as the baseline cost for employees to acquire these shares, reflecting the valuation parameters set by the committee at the time of grant.

The company’s Group General Counsel & Group Chief Compliance Officer, Babu Rao P., certified the disclosure to the National Stock Exchange of India Ltd. and BSE Limited. The filing ensures transparency regarding the equity compensation structure and its adherence to regulatory frameworks governing share-based benefits in India.

Historical Stock Returns for Religare Enterprises

1 Day5 Days1 Month6 Months1 Year5 Years
-0.69%+8.58%-2.01%+17.08%+2.72%+61.66%

How might the ₹227.35 exercise price influence employee retention rates if Religare Enterprises' stock price underperforms market benchmarks over the next five years?

What is the potential impact on diluted EPS and shareholder equity once the 13,195 options begin vesting and are subsequently exercised?

How does this specific ESOP grant compare to previous compensation structures in terms of aligning long-term management goals with shareholder value?

More News on Religare Enterprises

1 Year Returns:+2.72%